Seagen Inc. SGEN
Day range unavailable
52-week range unavailable
- Market cap
- 43.15B
- Revenue (ttm)
- 2.30B
- Profit margin
- -32.61%
- Shares out
- 188.66M
- Forward P/E
- -156.67
- Beta
- 0.32
- Analysts
- Buy
- Price target
- 229.00 (+0.1%)
- Earnings date
- Nov 1, 2023
ALL +163.93 (+252.94%)
Key statistics
- Enterprise value
- 42.04B
- PEG ratio
- 0.55
- Price / sales
- 18.76
- Price / book
- 16.92
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 27.10%
- Free cash flow
- -277.09M
- Total cash
- 1.24B
- Total debt
- 124.58M
- Return on equity
- -27.93%
- Short % of float
- 6.79%
- 50-day average
- 217.43
- 200-day average
- 204.65
Analyst view
Consensus: buy
- Strong buy3
- Buy5
- Hold8
- Sell0
- Strong sell0
Next earnings
Nov 1, 2023
Expected Nov 1, 2023. Consensus EPS estimate -1.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 1, 2023 | Sep 1, 2023 | -0.71 | — | — | — |
| Aug 2, 2023 | Jun 1, 2023 | -0.78 | — | — | — |
| Apr 27, 2023 | Mar 1, 2023 | -0.82 | — | — | — |
| Feb 15, 2023 | Dec 1, 2022 | -1.02 | — | — | — |
| Oct 27, 2022 | Sep 1, 2022 | -0.92 | — | — | — |
| Jul 28, 2022 | Jun 1, 2022 | -0.82 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 17, 2023 | Truist Securities | reit | Hold | Hold |
| Sep 24, 2023 | Truist Securities | reit | Hold | Hold |
| Aug 2, 2023 | Morgan Stanley | reit | Equal-Weight | Equal-Weight |
| Mar 23, 2023 | Berenberg | down | Buy | Hold |
| Mar 20, 2023 | TD Securities | main | — | Market Perform |
| Mar 19, 2023 | Truist Securities | main | — | Hold |
About Seagen Inc.
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. It offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of adult patients with advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. The company also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-TGT and SEA-CD70 for various cancer diseases. It has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and RemeGen, Co. Ltd. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington. As of December 14, 2023, Seagen Inc. operates as a subsidiary of Pfizer Inc.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- seagen.com
News
Earnings Scheduled For November 1, 2023 
Earnings Scheduled For August 2, 2023 - Earnings Scheduled For April 27, 2023
Benzinga's Top Ratings Upgrades, Downgrades For March 14, 2023 
Earnings Scheduled For February 15, 2023 - Benzinga's Top Ratings Upgrades, Downgrades For February 6, 2023
- RH To Rally Over 15%? Here Are 10 Other Analyst Forecasts For Monday
Earnings Scheduled For October 27, 2022 
Why Aridis Pharmaceuticals Shares Plunged Around 30%; Here Are 81 Biggest Movers From Yesterday - Why LAVA Therapeutics Shares Are Trading Higher By 97%, Here Are 49 Stocks Moving In Monday's Mid-Day Session
Your note
Sign in to keep a note on SGEN — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BAKER BROS ADVISORS L.P. | Beneficial Owner of more than 10% of a Class of Security | Stock Award(Grant) | May 30, 2023 | 0 |
| DANSEY ROGER D | Officer | Sale | Sep 20, 2023 | 116,677 |
| EPSTEIN DAVID R | Chief Executive Officer | Sale | Nov 9, 2023 | 136,598 |
| GRYSKA DAVID W | Director | Stock Award(Grant) | May 30, 2023 | 51,047 |
| HIMES VAUGHN B | Chief Technology Officer | Sale | Nov 8, 2023 | 162,045 |
| LIU JEAN I | Officer | Sale | Sep 20, 2023 | 84,398 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Baker Brothers Advisors, LLC | 23.74% | 44,554,162 | 8.57B | Jun 29, 2023 |
| Vanguard Group Inc | 7.09% | 13,315,658 | 2.56B | Jun 29, 2023 |
| Blackrock Inc. | 6.42% | 12,041,819 | 2.32B | Jun 29, 2023 |
| Pentwater Capital Management Lp | 5.13% | 9,629,500 | 1.85B | Jun 29, 2023 |
| Capital World Investors | 4.84% | 9,081,409 | 1.75B | Jun 29, 2023 |
| Capital International Investors | 3.42% | 6,417,224 | 1.24B | Jun 29, 2023 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Growth Fund Of America Inc | 3.52% | 6,610,163 | 1.27B | Jun 29, 2023 |
| Vanguard Total Stock Market Index Fund | 2.34% | 4,396,581 | 846.17M | Jun 29, 2023 |
| Vanguard Mid-Cap Index Fund | 1.74% | 3,259,531 | 627.33M | Jun 29, 2023 |
| Invesco ETF Tr-Invesco QQQ Tr, Series 1 ETF | 1.69% | 3,177,667 | 654.82M | Aug 30, 2023 |
| Vanguard Horizon Fund-Capital Opportunity Fund | 1.21% | 2,274,960 | 437.84M | Jun 29, 2023 |
| New Perspective Fund Inc | 1.20% | 2,260,964 | 435.15M | Jun 29, 2023 |